Stocks · News reference
Yakira urges Board to explore strategic alternatives before further cash burn and dilution erode shareholder value; questions decision to raise $50 million after shares fell approximately 44% at a valuation near fifty
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Atrium Therapeutics announced it will present new nonclinical data for its investigational therapy ATR 1072, intended for the treatment of PRKAG2 syndrome, at the upcoming American Heart Association Scientific Sessions.
Filed: 2026-11-02 AccNo: 0001193125-26-442601 Size: 13 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
HC Wainwright & Co. has reduced its price target for Atrium Therapeutics, Inc. from $25.00 to $20.00 per share.
Atrium Therapeutics has initiated the Phase 1/2 Corventis clinical trial by dosing the first patient with ATR 1072 for the treatment of PRKAG2 syndrome.
Analysts initiated coverage: Buy ratings for CleanSpark, Constellation Energy and Atrium; Outperform for Kardigan; Neutral for Northwest Natural.
Roth Capital has initiated research coverage on Atrium Therapeutics, Inc. with a Buy rating.